scholarly journals Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options

2014 ◽  
pp. 777 ◽  
Author(s):  
Pierre Chue ◽  
Justine Lalonde
Keyword(s):  
Pharmacological Treatment ◽  
Negative Symptoms ◽  
Unmet Needs ◽  
Treatment Options ◽  
Persistent Negative Symptoms

scholarly journals Exploring Unmet Needs from an Online Metastatic Breast Cancer Support Group: A Qualitative Study

Medicina ◽  
2021 ◽  
Vol 57 (7) ◽  
pp. 693
Author(s):  
Aravinthan Kadravello ◽  
Seng-Beng Tan ◽  
Gwo-Fuang Ho ◽  
Ranjit Kaur ◽  
Cheng-Har Yip
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Support Group ◽  
Unmet Needs ◽  
Treatment Options ◽  
Metastatic Breast ◽  
Public Hospitals ◽  
Online Support ◽  
Online Support Group ◽  
The Public

Background and Objective: Despite the increasing treatment options for patients with metastatic breast cancer (MBC), unmet needs remain common, especially in low and middle-income countries where resources are limited and MBC patients face many challenges. They often join support groups to cope with their unmet needs. Currently, many MBC patients connect with each other via online support group in view of the constant availability of support and rapid information exchange. The objective of this study is to determine the unmet needs of women with MBC from an online support group. Material and Methods: Messages in an online support group of twenty-two MBC patients over a period of three years from August 2016 till August 2019 were thematically analyzed. Results: Three themes were generated, (1) unmet information needs (2) unmet financial needs (3) unmet support needs. Women needed information on side effects of treatment, new treatment options and availability of clinical trials. Although Malaysia has universal health care coverage, access to treatment remains a major challenge. When treatment was not available in the public hospitals, or waiting lists were too long, women were forced to seek treatment in private hospitals, incurring financial catastrophe. Insufficient private insurance and inadequate social security payments force many women to consider stopping treatment. Women felt that they were not getting support from their clinicians in the public sector, who were quick to stop active treatment and advise palliation. On the other hand, clinicians in the private sector advise expensive treatment beyond the financial capability of the patients. Women with families also face the challenge of managing their family and household in addition to coping with their illness. Conclusions: There is a need for healthcare professionals, policy makers, and civil society to better address the needs of MBC patients through patient-centered, multidisciplinary and multi-organizational collaboration.

scholarly journals Addressing Anxiety and Fear during the Female Pelvic Examination

2021 ◽  
Vol 12 ◽  
pp. 215013272199219
Author(s):  
Danielle J. O’Laughlin ◽  
Brittany Strelow ◽  
Nicole Fellows ◽  
Elizabeth Kelsey ◽  
Sonya Peters ◽  
...  
Keyword(s):  
Risk Factors ◽  
Health Care Providers ◽  
Negative Symptoms ◽  
Behavioral Therapy ◽  
Treatment Options ◽  
Pelvic Examination ◽  
Care Providers ◽  
Emotional Symptoms ◽  
Pelvic Examinations ◽  
Anxiety And Fear

To review the anxiety and fear risk factors, pathophysiology, symptoms, screening and diagnosis while highlighting treatment considerations for women undergoing a pelvic examination. Methods: We reviewed the literature pertaining to anxiety and fear surrounding the pelvic examination to help guide health care providers’ on available screening options and to review options for individualized patient management. Results: Anxiety and fear are common before and during the pelvic examination. In fact, the pelvic exam is one of the most common anxiety-provoking medical procedures. This exam can provoke negative physical and emotional symptoms such as pain, discomfort, anxiety, fear, embarrassment, and irritability. These negative symptoms can interfere with preventative health screening compliance resulting in delayed or avoided care and significant health consequences. Conclusion: Assessing women for anxiety related to pelvic examinations may help decrease a delay or avoidance of examinations. Risk factor and symptom identification is also a key component in this. General anxiety questionnaires can help identify women with anxiety related to pelvic examinations. Strategies to reduce anxiety, fear and pain during a pelvic examination should routinely be implemented, particularly in women with high-risk factors or those identified with screening techniques as having anxiety, fear or pain with examinations. Treatment options should be targeted at understanding the patient’s concerns, starting conversations about pelvic examinations early, educating patient’s about the examination and offering the presence of a chaperone or support person. During an examination providers should ensure the patient is comfortable, negative phrases are avoided, the correct speculum size is utilized and proper lubrication, draping, dressing and positioning are performed. Treating underlying gynecologic or mental health conditions, consideration of cognitive behavioral therapy and complementary techniques such as lavender aromatherapy and music therapy should also be considered when appropriate.

scholarly journals Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus

2021 ◽  
Author(s):  
Hitoshi Sakurai ◽  
Norio Yasui-Furukori ◽  
Takefumi Suzuki ◽  
Hiroyuki Uchida ◽  
Hajime Baba ◽  
...  
Keyword(s):  
Relapse Prevention ◽  
Negative Symptoms ◽  
Japanese Society ◽  
Treatment Guidelines ◽  
Treatment Options ◽  
Standard Deviation Score ◽  
Expert Consensus ◽  
Depression And Anxiety ◽  
First Line ◽  
A Current

Abstract Introduction Conventional treatment guidelines of schizophrenia do not necessarily provide solutions on clinically important issues. Methods A total of 141 certified psychiatrists of the Japanese Society of Clinical Neuropsychopharmacology evaluated treatment options regarding 19 clinically relevant situations in the treatment of schizophrenia with a 9-point scale (1=“disagree” and 9=“agree”). Results First-line antipsychotics varied depending on predominant symptoms: risperidone (mean±standard deviation score, 7.9±1.4), olanzapine (7.5±1.6), and aripiprazole (6.9±1.9) were more likely selected for positive symptoms; aripiprazole (7.6±1.6) for negative symptoms; aripiprazole (7.3±1.9), olanzapine (7.2±1.9), and quetiapine (6.9±1.9) for depression and anxiety; and olanzapine (7.9±1.5) and risperidone (7.5±1.5) for excitement and aggression. While only aripiprazole was categorized as a first-line treatment for relapse prevention (7.6±1.0) in patients without noticeable symptoms, aripiprazole (8.0±1.6) and brexpiprazole (6.9±2.3) were categorized as such for social integration. First-line treatments in patients who are vulnerable to extrapyramidal symptoms include quetiapine (7.5±2.0) and aripiprazole (6.9±2.1). Discussion These clinical recommendations represent the expert consensus on the use of a particular antipsychotic medication for a particular situation, filling a current gap in the literature.

scholarly journals The safety of pharmacological treatment options for lupus nephritis

2016 ◽  
Vol 15 (8) ◽  
pp. 1041-1054 ◽  
Author(s):  
Alba Velo-García ◽  
Eleana Ntatsaki ◽  
David Isenberg
Keyword(s):  
Lupus Nephritis ◽  
Pharmacological Treatment ◽  
Treatment Options

scholarly journals Linking persistent negative symptoms to amygdala–hippocampus structure in first-episode psychosis

2017 ◽  
Vol 7 (8) ◽  
pp. e1195-e1195 ◽  
Author(s):  
C Makowski ◽  
M Bodnar ◽  
J J Shenker ◽  
A K Malla ◽  
R Joober ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
First Episode Psychosis ◽  
First Episode ◽  
Episode Psychosis ◽  
Persistent Negative Symptoms

scholarly journals Mobile-Assisted Cognitive Behavioral Therapy for Negative Symptoms: Open Single-Arm Trial With Schizophrenia Patients

10.2196/24406 ◽  
2020 ◽  
Vol 7 (12) ◽  
pp. e24406
Author(s):  
Eric Granholm ◽  
Jason Holden ◽  
Kristen Dwyer ◽  
Tanya Mikhael ◽  
Peter Link ◽  
...  
Keyword(s):  
Cognitive Behavioral Therapy ◽  
Negative Symptoms ◽  
Behavioral Therapy ◽  
Therapy Group ◽  
Controlled Trial ◽  
Psychosocial Interventions ◽  
Cognitive Behavioral ◽  
Unmet Treatment Need ◽  
Attitude Model ◽  
Persistent Negative Symptoms

Background Negative symptoms are an important unmet treatment need for schizophrenia. This study is a preliminary, open, single-arm trial of a novel hybrid intervention called mobile-assisted cognitive behavioral therapy for negative symptoms (mCBTn). Objective The primary aim was to test whether mCBTn was feasible and could reduce severity of the target mechanism, defeatist performance attitudes, which are associated with experiential negative symptoms and poor functioning in schizophrenia. Methods Participants with schizophrenia or schizoaffective disorder (N=31) who met prospective criteria for persistent negative symptoms were enrolled. The blended intervention combines weekly in-person group therapy with a smartphone app called CBT2go. The app extended therapy group skills, including recovery goal setting, thought challenging, scheduling of pleasurable activities and social interactions, and pleasure-savoring interventions to modify defeatist attitudes and improve experiential negative symptoms. Results Retention was excellent (87% at 18 weeks), and severity of defeatist attitudes and experiential negative symptoms declined significantly in the mCBTn intervention with large effect sizes. Conclusions The findings suggest that mCBTn is a feasible and potentially effective treatment for experiential negative symptoms, if confirmed in a larger randomized controlled trial. The findings also provide support for the defeatist attitude model of experiential negative symptoms and suggest that blended technology-supported interventions such as mCBTn can strengthen and shorten intensive psychosocial interventions for schizophrenia. Trial Registration ClinicalTrials.gov NCT03179696; https://clinicaltrials.gov/ct2/show/NCT03179696

Sign in / Sign up

Export Citation Format

Share Document